CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY

Erwan Hermawan, Nur Anis Hadiyati, Adiarso Adiarso, Ermawan Darma Setiyadi, Siti Zunuraen, Dudi Hidayat, Anwar Wahyudi, Hartini Ahadiyatur Ru’yi
{"title":"CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY","authors":"Erwan Hermawan, Nur Anis Hadiyati, Adiarso Adiarso, Ermawan Darma Setiyadi, Siti Zunuraen, Dudi Hidayat, Anwar Wahyudi, Hartini Ahadiyatur Ru’yi","doi":"10.20473/jaki.v11i2.2023.196-211","DOIUrl":null,"url":null,"abstract":"Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives. Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022. Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D. Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera. Keywords: pharmaceutical raw materials, policy, pharmaceutical","PeriodicalId":32968,"journal":{"name":"Jurnal Administrasi Kesehatan Indonesia","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Administrasi Kesehatan Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20473/jaki.v11i2.2023.196-211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives. Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022. Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D. Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera. Keywords: pharmaceutical raw materials, policy, pharmaceutical
印度尼西亚制药原料行业面临的挑战和政策支持
背景:印尼制药业正面临诸多挑战,特别是其原材料大多为进口产品。导致医药原料行业面临挑战的几个因素包括:缺乏对技术的掌握、缺乏政府支持、研发预算低、研发成本高且耗时、创新激励机制低。研究目的:本研究旨在对印尼医药原料产业的发展战略进行研究:本研究采用定性方法,从与多个行业和机构的访谈和讨论中收集数据进行三角分析。研究于 2022 年进行,为期六个月。研究结果要使医药原料产业蓬勃发展,需要实施的政策有:(i)有明确的大战略;(ii)根据产业需求确定医药原料的优先次序;(iii)保护国内产品;(iv)增加卫生支出;(v)加强基础化学产品;(vi)增加研发预算。结论:可以加强的一些政策包括提供有利于本地医药原料产业的激励措施和政策,包括规范价格、结束对进口产品的依赖、税收激励、通过进口关税政策保护国内产品、能源补贴、技术转让等。关键词:医药原料、政策、制药
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
16
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信